Cats and Helicobacter

Takemura, L. S., P. L. Camargo, et al. (2009). "Helicobacter spp. in cats: association between infecting species and epithelial proliferation within the gastric lamina propria." J Comp Pathol 141(2-3): 127-34.

Helicobacter are bacteria that colonize the gastric lumen and duodenum. In humans, these bacteria have been linked to gastritis, gastric ulcers, and gastric adenocarcinomas. The prevalence of Helicobacter in cats is high, but it is not known if there is an associated risk of gastric lesions. In this study, gastric samples were collected from 23 cats; 18 with no clinical signs, and 5 that had chronic vomiting. Samples were assessed microscopically for epithelial changes, as well as by PCR for the organism. The bacteria were detected in 20 of the 23 cats, four of which were from the cats experiencing chronic vomiting. No correlation was found between gastric inflammation and level of Helicobacter colonization. Helicobacter colonization was associated with increased epithelial proliferation in the stomach; thus, the authors postulate, it could contribute to gastric cancers. [MK]
>> PubMed Abstract

Related articles:
Greiter-Wilke, A., E. Scanziani, et al. (2006). "Association of Helicobacter with cholangiohepatitis in cats." J Vet Intern Med 20(4): 822-7.
>> PubMed Abstract

Bridgeford, E. C., R. P. Marini, et al. (2008). "Gastric Helicobacter species as a cause of feline gastric lymphoma: A viable hypothesis." Vet Immunol Immunopathol 123(1-2): 106-13.
>> Free, full text article

More on cat health: Winn Feline Foundation Library
Join us on Facebook

Cerenia for Nausea in Cats

Hickman, M. A., S. R. Cox, et al. (2008). "Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats." Journal of Veterinary Pharmacology and Therapeutics 31(3): 220-229.

Maropitant (Cerenia, Pfizer Animal Health) is a selective NK-1 receptor antagonist that has anti-emetic effects. It is licensed for oral use in dogs in the United States. In this study, maropitant was administered to cats at doses ranging from 0.5 to 5.0 mg/kg subcutaneously (SC) for 15 days. No adverse effects were found at any dose, including doses that exceed the anti-emetic dose by a factor of 10. The pharmacokinetics of maropitant were determined following single dose oral, intravenous, and SC administration. Anti-emesis efficacy was determined against xylazine or motion. A dosage of 1 mg/kg maropitant administered IV, SC or PO prevented emesis elicited by xylazine. The results indicate that maropitant is an effective, well tolerated and safe anti-emetic in cats at a dose of 1.0 mg/kg with a 24-hour duration of action.
>> PubMed abstract

Related articles:
de la Puente-Redondo, V. A., E. M. Siedek, et al. (2007). "The anti-emetic efficacy of maropitant (Cerenia) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe." J Small Anim Pract 48(2): 93-8.
>> PubMed abstract

More on cat health: Winn Feline Foundation Library